Genevant is focusing on the development and delivery of RNA-based therapeutics. A major limitation to the deployment of RNA-based therapies is safe and effective delivery. Lipid nanoparticles (LNPs) are a broad delivery modality class that can be engineered by composition, formulation and manufacture to achieve favorable pharmacological properties. Genevant’s proprietary LNP platform enables the identification of LNPs with optimal uptake into desired cells and efficient release of cargo to target tissue.
Genevant has created the world’s only approved small interfering RNA-LNP product and has several other disease programs in development or clinical trials for antiviral, oncology and metabolic disorders.